Paper Details

  1. Home
  2. Paper Details

Canadian Experience with Fingolimod: Adherence to Treatment and Monitoring.

Author: DevonshireVirginia, FreedmanMark S, KremenchutzkyMarcelo, LapierreYves, O'ConnorPaul, SchecterRobyn, YeungMichael

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The GILENYA® Go ProgramTM captures data for virtually all fingolimod-treated patients in Canada. Ongoing patient support and reminders to take the medication resulted in a high rate of continuation during longer-term therapy.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The Canadian GILENYA® Go ProgramTM provides education and support to people with relapsing-remitting multiple sclerosis during fingolimod treatment. METHODS: Data were collected and analyzed from the time of the first individual enrolled in March 2011 to March 31, 2014. Individuals were...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1017/cjn.2015.325

データ提供：米国国立医学図書館（NLM）

Fingolimod: A Guiding Camel in the Desert of Multiple Sclerosis

Multiple sclerosis (MS) is a complex and unpredictable disease. This research examines the Canadian experience with fingolimod, a medication used to treat relapsing-remitting MS. The study investigates the adherence to treatment and monitoring of fingolimod, focusing on the effectiveness and safety of this medication in real-world clinical practice. This is like charting a path through the desert of MS, trying to find the most effective and safe route to treatment.

Fingolimod: A Reliable Guide through the Desert of MS

The study found that the GILENYA® Go ProgramTM resulted in high continuation rates with fingolimod during long-term therapy. This suggests that fingolimod is a valuable tool for managing MS, offering hope for improved quality of life for patients. This is like finding a reliable guide in the desert, leading patients to a more stable and manageable future.

Navigating the Challenges of MS Treatment

The research underscores the importance of ongoing patient support and monitoring in managing MS. This research is like mapping out a route through the desert, ensuring that patients have the necessary resources and guidance to navigate the challenges of living with MS.

Dr. Camel's Conclusion

This study demonstrates the potential of fingolimod in managing MS. The high continuation rates and low discontinuation rate due to lack of efficacy highlight the importance of patient support and monitoring. This research is like discovering a new oasis in the desert of MS, offering hope for a brighter future for patients with this complex disease.

Date :
  1. Date Completed 2016-12-13
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

26890887

DOI: Digital Object Identifier

10.1017/cjn.2015.325

Related Literature

Article Analysis
・Effects of glatiramer injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.